These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

514 related items for PubMed ID: 26513298

  • 1. E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling.
    McGonigle S, Chen Z, Wu J, Chang P, Kolber-Simonds D, Ackermann K, Twine NC, Shie JL, Miu JT, Huang KC, Moniz GA, Nomoto K.
    Oncotarget; 2015 Dec 01; 6(38):41307-23. PubMed ID: 26513298
    [Abstract] [Full Text] [Related]

  • 2. Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer.
    Zhou Q, Ji M, Zhou J, Jin J, Xue N, Chen J, Xu B, Chen X.
    Biochem Pharmacol; 2016 May 01; 107():29-40. PubMed ID: 26920250
    [Abstract] [Full Text] [Related]

  • 3. Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells.
    Ma L, Wang X, Jia T, Wei W, Chua MS, So S.
    Oncotarget; 2015 Sep 22; 6(28):25390-401. PubMed ID: 26246473
    [Abstract] [Full Text] [Related]

  • 4. Dissecting the molecular determinants of clinical PARP1 inhibitor selectivity for tankyrase1.
    Ryan K, Bolaňos B, Smith M, Palde PB, Cuenca PD, VanArsdale TL, Niessen S, Zhang L, Behenna D, Ornelas MA, Tran KT, Kaiser S, Lum L, Stewart A, Gajiwala KS.
    J Biol Chem; 2021 Sep 22; 296():100251. PubMed ID: 33361107
    [Abstract] [Full Text] [Related]

  • 5. Rational design, synthesis and biological evaluation of dual PARP-1/2 and TNKS1/2 inhibitors for cancer therapy.
    Xu Y, Wu H, Huang L, Zhai B, Li X, Xu S, Wu X, Zhu Q, Xu Q.
    Eur J Med Chem; 2022 Jul 05; 237():114417. PubMed ID: 35504210
    [Abstract] [Full Text] [Related]

  • 6. Evidence for tankyrases as antineoplastic targets in lung cancer.
    Busch AM, Johnson KC, Stan RV, Sanglikar A, Ahmed Y, Dmitrovsky E, Freemantle SJ.
    BMC Cancer; 2013 Apr 28; 13():211. PubMed ID: 23621985
    [Abstract] [Full Text] [Related]

  • 7. Study of the mechanism by which Xiaoyan decoction combined with E7449 regulates tumorigenesis in lung adenocarcinoma.
    Zheng X, Han Y, Gu L, Gao S, Lv Y, Li C.
    J Cell Mol Med; 2024 Jun 28; 28(12):e18467. PubMed ID: 38898581
    [Abstract] [Full Text] [Related]

  • 8. Identification and preclinical characterization of a novel and potent poly (ADP-ribose) polymerase (PARP) inhibitor ZYTP1.
    Jain MR, Mohapatra J, Bandhyopadhyay D, Chatterjee A, Ghoshdastidar K, Patel D, Patel A, Bhayani H, Srivastava BK, Shedage SA, Kadam P, Sundar R, Patel H, Giri P, Patel P, Gupta L, Srinivas NR, Patel PR, Desai RC.
    Cancer Chemother Pharmacol; 2018 Oct 28; 82(4):635-647. PubMed ID: 30046848
    [Abstract] [Full Text] [Related]

  • 9. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
    Yuan B, Ye N, Song SS, Wang YT, Song Z, Chen HD, Chen CH, Huan XJ, Wang YQ, Su Y, Shen YY, Sun YM, Yang XY, Chen Y, Guo SY, Gan Y, Gao ZW, Chen XY, Ding J, He JX, Zhang A, Miao ZH.
    Cancer Lett; 2017 Feb 01; 386():47-56. PubMed ID: 27847302
    [Abstract] [Full Text] [Related]

  • 10. First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor.
    Plummer R, Dua D, Cresti N, Drew Y, Stephens P, Foegh M, Knudsen S, Sachdev P, Mistry BM, Dixit V, McGonigle S, Hall N, Matijevic M, McGrath S, Sarker D.
    Br J Cancer; 2020 Aug 01; 123(4):525-533. PubMed ID: 32523090
    [Abstract] [Full Text] [Related]

  • 11. The Discovery and Characterization of K-756, a Novel Wnt/β-Catenin Pathway Inhibitor Targeting Tankyrase.
    Okada-Iwasaki R, Takahashi Y, Watanabe Y, Ishida H, Saito J, Nakai R, Asai A.
    Mol Cancer Ther; 2016 Jul 01; 15(7):1525-34. PubMed ID: 27196752
    [Abstract] [Full Text] [Related]

  • 12. Combined EGFR1 and PARP1 Inhibition Enhances the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Models.
    Frederick BA, Gupta R, Atilano-Roque A, Su TT, Raben D.
    Radiat Res; 2020 Nov 10; 194(5):519-531. PubMed ID: 32936912
    [Abstract] [Full Text] [Related]

  • 13. Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma.
    Chornenkyy Y, Agnihotri S, Yu M, Buczkowicz P, Rakopoulos P, Golbourn B, Garzia L, Siddaway R, Leung S, Rutka JT, Taylor MD, Dirks PB, Hawkins C.
    Mol Cancer Ther; 2015 Nov 10; 14(11):2560-8. PubMed ID: 26351319
    [Abstract] [Full Text] [Related]

  • 14. Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer.
    García-Parra J, Dalmases A, Morancho B, Arpí O, Menendez S, Sabbaghi M, Zazo S, Chamizo C, Madoz J, Eroles P, Servitja S, Tusquets I, Yelamos J, Lluch A, Arribas J, Rojo F, Rovira A, Albanell J.
    Eur J Cancer; 2014 Oct 10; 50(15):2725-34. PubMed ID: 25128455
    [Abstract] [Full Text] [Related]

  • 15. Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials.
    Wang L, Yang C, Xie C, Jiang J, Gao M, Fu L, Li Y, Bao X, Fu H, Lou L.
    Cancer Sci; 2019 Mar 10; 110(3):1064-1075. PubMed ID: 30663191
    [Abstract] [Full Text] [Related]

  • 16. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency.
    Shen Y, Rehman FL, Feng Y, Boshuizen J, Bajrami I, Elliott R, Wang B, Lord CJ, Post LE, Ashworth A.
    Clin Cancer Res; 2013 Sep 15; 19(18):5003-15. PubMed ID: 23881923
    [Abstract] [Full Text] [Related]

  • 17. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.
    Du Y, Yamaguchi H, Wei Y, Hsu JL, Wang HL, Hsu YH, Lin WC, Yu WH, Leonard PG, Lee GR, Chen MK, Nakai K, Hsu MC, Chen CT, Sun Y, Wu Y, Chang WC, Huang WC, Liu CL, Chang YC, Chen CH, Park M, Jones P, Hortobagyi GN, Hung MC.
    Nat Med; 2016 Feb 15; 22(2):194-201. PubMed ID: 26779812
    [Abstract] [Full Text] [Related]

  • 18. The Poly(ADP-ribose) Polymerase Enzyme Tankyrase Antagonizes Activity of the β-Catenin Destruction Complex through ADP-ribosylation of Axin and APC2.
    Croy HE, Fuller CN, Giannotti J, Robinson P, Foley AVA, Yamulla RJ, Cosgriff S, Greaves BD, von Kleeck RA, An HH, Powers CM, Tran JK, Tocker AM, Jacob KD, Davis BK, Roberts DM.
    J Biol Chem; 2016 Jun 10; 291(24):12747-12760. PubMed ID: 27068743
    [Abstract] [Full Text] [Related]

  • 19. Tankyrase Inhibitors Stimulate the Ability of Tankyrases to Bind Axin and Drive Assembly of β-Catenin Degradation-Competent Axin Puncta.
    Martino-Echarri E, Brocardo MG, Mills KM, Henderson BR.
    PLoS One; 2016 Jun 10; 11(3):e0150484. PubMed ID: 26930278
    [Abstract] [Full Text] [Related]

  • 20. Activation of Wnt signaling promotes olaparib resistant ovarian cancer.
    Yamamoto TM, McMellen A, Watson ZL, Aguilera J, Ferguson R, Nurmemmedov E, Thakar T, Moldovan GL, Kim H, Cittelly DM, Joglar AM, Brennecke EP, Wilson H, Behbakht K, Sikora MJ, Bitler BG.
    Mol Carcinog; 2019 Oct 10; 58(10):1770-1782. PubMed ID: 31219654
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.